Grifols Procleix Panther System with Automation Ready Technology (ART) Receives FDA Approval


Barcelona, ​​Spain, May 7, 2020 / PRNewswire / – Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), one of the world’s leading producers of plasma-derived drugs and a leader in the development of innovative diagnostic solutions, announced today hui have received FDA approval for the Procleix Panther System with ART for use with the following US licensed products: Procleix Ultrio Elite Assay, Procleix WNV Assay, Procleix Zika Virus Assay and Procleix Babesia Assay.

Building on the success of the Procleix Panther system, ART technology features significant hardware and software enhancements that support blood bank operations of all sizes, such as instrument networking and information sharing.

ART supports laboratory efforts to achieve full sample automation. It offers increased control over the workflow and use of personnel, from standard to complex processes. It also allows for simplified user management through connecting multiple instruments to a track system for automated sample handling.

The Procleix Panther system with ART is expected to strengthen the company’s leadership in this market segment. It has been available since October 2019 in all markets that accept CE marking.

“The FDA approval is another important recognition for Grifols and its commitment to deliver innovative solutions to our US customers, especially in these challenging times when increased automation can allow key laboratory personnel to be assigned to work. ‘other priority tasks,’ said Carsten Schroeder, President and CEO, Grifols Diagnostic Solutions Inc. “As a market leader in the donor screening segment, Grifols will continue to partner with blood banks around the world as part of its mission to improve patient welfare and blood safety. “

About the Procleix Panther System

The Procleix Panther system automates all aspects of NAT (Nucleic Acid Technology) based blood screening on a single integrated platform and is capable of delivering the highest throughput of results per square meter. It eliminates the need for batch processing and combines walking freedom with an intuitive design for easy operation.

Improvements in ART technology further increase the versatility of the system, offering customizable options and more functionality on demand to adapt to the changing needs and budgets of blood banks around the world.

About Procleix NAT Solutions

Today, Procleix systems are used to screen more donated blood globally than any other NAT blood screening product, and include testing for HIV, hepatitis viruses (A, B, C and E ), West Nile virus, SARS-CoV-2 *, Zika virus, dengue virus, Babesia, and more.

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions – Bioscience, Diagnostics, Hospital and Bio Supplies – develop, produce and market innovative solutions and services which are sold in more than 100 countries.

Pioneers in the plasma industry, Grifols operates a growing network of donation centers around the world. It transforms the collected plasma into essential medicines to treat rare, chronic and sometimes fatal diseases. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to improve the safety of donation to transfusion. In addition, the company provides tools, information and services that enable hospitals, pharmacies and healthcare professionals to effectively deliver specialized medical care.

Grifols, with more than 24,000 employees in 30 countries, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

In 2019, Grifols’ economic impact in its main countries of operation was 8.5 billion euros. The company has also generated 148,000 jobs, including indirect and induced.

The company’s Class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE: GRF). Grifols Class B non-voting shares are listed on the Mercado Continuo (MCE: GRF.P) and on the US NASDAQ via ADRs (NASDAQ: GRFS).

For more information, please visit

Product registration and availability vary by country.

Procleix is ​​a registered trademark of Grifols Worldwide Operations Limited.

Panther is a registered trademark of Hologic, Inc.

*in development. Performance characteristics have not been established

SOURCE Grifols, SA

Source link

Leave A Reply

Your email address will not be published.